Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials

R. Serna Blasco,M. R. Garcia Campelo,E. Nadal, P. Mediavilla,V. Calvo, J. L. Gonzalez-Larriba,L. Robado de Lope,B. Massuti,A. Martinez-Marti, J. Casal,M. Domine,M. Cobo,A. Cruz,A. Romero,M. Provencio

Journal of Thoracic Oncology（2023）

引用 0|浏览4

暂无评分

摘要

Neoadjuvant chemoimmunotherapy is the new standard of treatment for locally-advanced (stage IIIA-B) non-small-cell lung cancer (NSCLC) patients. In this study, we report preliminary results of potential molecular mechanisms underlying disease progression in patients treated with neoadjuvant nivolumab plus chemotherapy using plasma samples from NADIM and NADIM II cohorts.

查看译文

关键词

NADIM clinical trials,Neoadjuvant treatment,progression

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要